Cullinan Therapeutics, Inc. (CGEM) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha • Tuesday
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerGlobeNewsWire • 11/12/26
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewsWire • 11/10/26
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026GlobeNewsWire • 11/08/26
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual MeetingGlobeNewsWire • 11/04/26
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?Zacks Investment Research • 10/29/26
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDAGlobeNewsWire • 10/27/26
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS MetastasesBusiness Wire • 10/19/26
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewsWire • 10/08/26
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramGlobeNewsWire • 10/01/26
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune DiseasesSeeking Alpha • 09/29/26
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager PortfolioGlobeNewsWire • 09/24/26
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumGlobeNewsWire • 09/21/26
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung CancerGlobeNewsWire • 09/14/26
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerBusiness Wire • 09/13/26
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung CancerGlobeNewsWire • 09/10/26
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes ShapeBenzinga • 08/13/26
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsGlobeNewsWire • 08/06/26
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AMLGlobeNewsWire • 07/28/26